We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

The CHMP recommends approval for AZN's Wainzua for treating polyneuropathy associated with hereditary transthyretin-mediated ...

Check the time stamp on this data. Updated AI-Generated Signals for Ionis Pharmaceuticals Inc. (IONS) available here: IONS.

Avacta Therapeutics has entered a strategic collaboration with Tempus AI to advance the development of drugs in oncology.

AstraZeneca and Ionis are collaborating on the commercialisation of the drug following a December 2021 global agreement.